Andrew M. Lewis
Andrew M. Lewis has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Thomas Gunning
Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada
5 shared publications - Kilian V. M. Huber
Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
4 shared publications - Cheryl H. Arrowsmith
Structural Genomics Consortium, Toronto, ON, Canada
3 shared publications Daniel P. Ball
Department of Chemical and Physical Sciences, University of Toronto Mississauga, Mississauga, Ontario, L5L 1C6, Canada
3 shared publications- Jian Jin
Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
3 shared publications Mulu Geletu
Department of Chemical and Physical Sciences, University of Toronto at Mississauga, Mississauga, ON L5L 1C6, Canada
3 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Ligand-Directed Lysine Labelling of CRBN Enables Chemical Interrogation of a Key E3 Ligase Without Genetic Modification
Cereblon (CRBN) is the central substrate receptor of the CUL4 E3 ligase and a cornerstone of targeted protein degradation (TPD), yet no chemical tools exist to directly interrogate CRBN itself. We report ligand-directed, site-specific labelling probes for CRBN that install a bioorthogonal click handle directly onto the native protein surface. This chemical modification allows modular attachment of functional tags, enabling downstream functionalisation of CRBN for assay development in patient-derived samples and in cells that are difficult to genetically manipulate. Guided by computational reactivity predictions and structural distance mapping, we designed lysine-targeting probes based on thalidomide and phenyl-dihydrouracil scaffolds and validated their ability to covalently label CRBN in recombinant, lysate, and cellular contexts. Crystal structures of CRBN in complex with representative probes confirm a conserved binding mode anchored by the core scaffold, whilst conformational flexibility at the NASA linker corroborated by molecular docking, enables sampling of proximal lysine residues. Proteomic analysis revealed highly selective modification at Lys300 and Lys407, with no detectable off-target reactivity despite the presence of 50 putative nucleophilic residues. These probes provide the first non-genetic strategy to directly access and functionalise CRBN, expanding the TPD toolbox and enabling earlier evaluation of CRBN-targeting therapeutics in clinically relevant settings.
- 15 April 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessLigand-Directed Lysine Labelling of CRBN Enables Chemical Interrogation of a Key E3 Ligase Without Genetic Modification
Cereblon (CRBN) is the central substrate receptor of the CUL4 E3 ligase and a cornerstone of targeted protein degradation (TPD), yet no chemical tools exist to directly interrogate CRBN itself. We report ligand-directed, site-specific labelling probes for CRBN that install a bioorthogonal click handle directly onto the native protein surface. This chemical modification allows modular attachment of functional tags, enabling downstream functionalisation of CRBN for assay development in patient-derived samples and in cells that are difficult to genetically manipulate. Guided by computational reactivity predictions and structural distance mapping, we designed lysine-targeting probes based on thalidomide and phenyl-dihydrouracil scaffolds and validated their ability to covalently label CRBN in recombinant, lysate, and cellular contexts. Crystal structures of CRBN in complex with representative probes confirm a conserved binding mode anchored by the core scaffold, whilst conformational flexibility at the NASA linker corroborated by molecular docking, enables sampling of proximal lysine residues. Proteomic analysis revealed highly selective modification at Lys300 and Lys407, with no detectable off-target reactivity despite the presence of 50 putative nucleophilic residues. These probes provide the first non-genetic strategy to directly access and functionalise CRBN, expanding the TPD toolbox and enabling earlier evaluation of CRBN-targeting therapeutics in clinically relevant settings.
- 24 September 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (20) , 9008-9025
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function
Modifications of histone tails, including lysine/arginine methylation, provide the basis of a 'chromatin or histone code'. Proteins that con-tain 'reader' domains can bind to these modifications and form specific effector complexes, which ultimately mediate chromatin function. The spindlin1 (SPIN1) protein contains three Tudor methyl-lysine/arginine reader domains and was identified as a putative onco-gene and transcriptional co-activator. Here we report a SPIN1 chemi-cal probe inhibitor with low nanomolar in vitro activity, exquisite selectivity on a panel of methyl reader and writer proteins, and with submicromolar cellular activity. X-ray crystallography showed that this Tudor domain chemical probe simultaneously engages Tudor domains 1 and 2 via a bidentate binding mode. Small molecule inhibition and siRNA knockdown of SPIN1, as well as chemoproteomic studies, iden-tified genes which are transcriptionally regulated by SPIN1 in squa-mous cell carcinoma and suggest that SPIN1 may have a roll in cancer related inflammation and/or cancer metastasis.
- 24 September 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (20) , 9008-9025
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function
Modifications of histone tails, including lysine/arginine methylation, provide the basis of a 'chromatin or histone code'. Proteins that con-tain 'reader' domains can bind to these modifications and form specific effector complexes, which ultimately mediate chromatin function. The spindlin1 (SPIN1) protein contains three Tudor methyl-lysine/arginine reader domains and was identified as a putative onco-gene and transcriptional co-activator. Here we report a SPIN1 chemi-cal probe inhibitor with low nanomolar in vitro activity, exquisite selectivity on a panel of methyl reader and writer proteins, and with submicromolar cellular activity. X-ray crystallography showed that this Tudor domain chemical probe simultaneously engages Tudor domains 1 and 2 via a bidentate binding mode. Small molecule inhibition and siRNA knockdown of SPIN1, as well as chemoproteomic studies, iden-tified genes which are transcriptionally regulated by SPIN1 in squa-mous cell carcinoma and suggest that SPIN1 may have a roll in cancer related inflammation and/or cancer metastasis.
- Open Access
- 3 January 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
A chemical biology toolbox to study protein methyltransferases and epigenetic signaling
Protein methyltransferases (PMTs) comprise a major class of epigenetic regulatory enzymes with therapeutic relevance. Here we present a collection of chemical probes and associated reagents and data to elucidate the function of human and murine PMTs in cellular studies. Our collection provides inhibitors and antagonists that together modulate most of the key regulatory methylation marks on histones H3 and H4, providing an important resource for modulating cellular epigenomes. We describe a comprehensive and comparative characterization of the probe collection with respect to their potency, selectivity, and mode of inhibition. We demonstrate the utility of this collection in CD4+ T cell differentiation assays revealing the potential of individual probes to alter multiple T cell subpopulations which may have implications for T cell-mediated processes such as inflammation and immuno-oncology. In particular, we demonstrate a role for DOT1L in limiting Th1 cell differentiation and maintaining lineage integrity. This chemical probe collection and associated data form a resource for the study of methylation-mediated signaling in epigenetics, inflammation and beyond.
- 3 January 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
Open AccessA chemical biology toolbox to study protein methyltransferases and epigenetic signaling
Protein methyltransferases (PMTs) comprise a major class of epigenetic regulatory enzymes with therapeutic relevance. Here we present a collection of chemical probes and associated reagents and data to elucidate the function of human and murine PMTs in cellular studies. Our collection provides inhibitors and antagonists that together modulate most of the key regulatory methylation marks on histones H3 and H4, providing an important resource for modulating cellular epigenomes. We describe a comprehensive and comparative characterization of the probe collection with respect to their potency, selectivity, and mode of inhibition. We demonstrate the utility of this collection in CD4+ T cell differentiation assays revealing the potential of individual probes to alter multiple T cell subpopulations which may have implications for T cell-mediated processes such as inflammation and immuno-oncology. In particular, we demonstrate a role for DOT1L in limiting Th1 cell differentiation and maintaining lineage integrity. This chemical probe collection and associated data form a resource for the study of methylation-mediated signaling in epigenetics, inflammation and beyond.
- Open Access
- 14 September 2018
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 13 (10) , 2849-2854
Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors
Targeting the protein–protein interaction between p53 and MDM2/MDMX (MDM4) represents an attractive anticancer strategy for the treatment of p53-competent tumors. Several selective and potent MDM2 inhibitors have been developed and entered the clinic; however, the repertoire of MDMX antagonists is still limited. The arylmethylidenepyrazolinone SJ-172550 has been reported as a selective MDMX antagonist; yet, uncertainties about its mechanism of action have raised doubts about its use as a chemical probe. Here, we show that, in addition to its unclear mode of action, SJ-172550 is unstable in aqueous buffers, giving rise to side products of unknown biological activity. Using an SJ-172550-derived affinity probe, we observed promiscuous binding to cellular proteins whereas cellular thermal shift assays did not reveal a stabilizing effect on MDMX. Overall, our results raise further questions about the interpretation of data using SJ-172550 and related compounds to investigate cellular phenotypes.
- 14 September 2018
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 13 (10) , 2849-2854
Open AccessChemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors
Targeting the protein–protein interaction between p53 and MDM2/MDMX (MDM4) represents an attractive anticancer strategy for the treatment of p53-competent tumors. Several selective and potent MDM2 inhibitors have been developed and entered the clinic; however, the repertoire of MDMX antagonists is still limited. The arylmethylidenepyrazolinone SJ-172550 has been reported as a selective MDMX antagonist; yet, uncertainties about its mechanism of action have raised doubts about its use as a chemical probe. Here, we show that, in addition to its unclear mode of action, SJ-172550 is unstable in aqueous buffers, giving rise to side products of unknown biological activity. Using an SJ-172550-derived affinity probe, we observed promiscuous binding to cellular proteins whereas cellular thermal shift assays did not reveal a stabilizing effect on MDMX. Overall, our results raise further questions about the interpretation of data using SJ-172550 and related compounds to investigate cellular phenotypes.
- Open Access
A Chemical Biology Toolbox for the Study of Protein Methyltransferases and Epigenetic Signaling
SUMMARY: Protein methyltransferases (PMTs) comprise a major class of epigenetic regulatory enzymes with therapeutic relevance. Here we present a collection of chemical probes and associated reagents and data to elucidate the function of human and murine PMTs in cellular studies. Our collection provides inhibitors and antagonists that together modulate most of the key regulatory methylation marks on histones H3 and H4, providing an important resource for modulating cellular epigenomes. We describe a comprehensive and comparative characterization of the probe collection with respect to their potency, selectivity, and mode of inhibition. We demonstrate the utility of this collection in CD4 + T cell differentiation assays revealing the remarkable potential of individual probes to alter multiple T cell subpopulations with important implications for T cell-mediated processes such as inflammation and immuno-oncology. In particular, we demonstrate a role for DOT1L in limiting Th1 cell differentiation and maintaining lineage integrity.
Open AccessA Chemical Biology Toolbox for the Study of Protein Methyltransferases and Epigenetic Signaling
SUMMARY: Protein methyltransferases (PMTs) comprise a major class of epigenetic regulatory enzymes with therapeutic relevance. Here we present a collection of chemical probes and associated reagents and data to elucidate the function of human and murine PMTs in cellular studies. Our collection provides inhibitors and antagonists that together modulate most of the key regulatory methylation marks on histones H3 and H4, providing an important resource for modulating cellular epigenomes. We describe a comprehensive and comparative characterization of the probe collection with respect to their potency, selectivity, and mode of inhibition. We demonstrate the utility of this collection in CD4 + T cell differentiation assays revealing the remarkable potential of individual probes to alter multiple T cell subpopulations with important implications for T cell-mediated processes such as inflammation and immuno-oncology. In particular, we demonstrate a role for DOT1L in limiting Th1 cell differentiation and maintaining lineage integrity.
- 1 September 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (18) , 4542-4547
A selective inhibitor of the UFM1-activating enzyme, UBA5
- 1 September 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (18) , 4542-4547
A selective inhibitor of the UFM1-activating enzyme, UBA5
- Open Access
- 2 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (15) , 20669-20679
Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent
Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent
- 2 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (15) , 20669-20679
Open AccessSignal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent
Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent
- 25 September 2015
- Published by Wiley
- p. 281-300
Developing Inhibitors of STAT3: Targeting Downstream of the Kinases for Treating Disease
- 25 September 2015
- Published by Wiley
- p. 281-300
Developing Inhibitors of STAT3: Targeting Downstream of the Kinases for Treating Disease
- 10 August 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 6 (9) , 982-986
Identification of Bidentate Salicylic Acid Inhibitors of PTP1B
PTP1B is a master regulator in the insulin and leptin metabolic pathways. Hyper-activated PTP1B results in insulin resistance and is viewed as a key factor in the onset of type II diabetes and obesity. Moreover, inhibition of PTP1B expression in cancer cells dramatically inhibits cell growth in vitro and in vivo. Herein, we report the computationally guided optimization of a salicylic acid-based PTP1B inhibitor 6, identifying new and more potent bidentate PTP1B inhibitors, such as 20h, which exhibited a > 4-fold improvement in activity. In CHO-IR cells, 20f, 20h, and 20j suppressed PTP1B activity and restored insulin receptor phosphorylation levels. Notably, 20f, which displayed a 5-fold selectivity for PTP1B over the closely related PTPσ protein, showed no inhibition of PTP-LAR, PRL2 A/S, MKPX, or papain. Finally, 20i and 20j displayed nanomolar inhibition of PTPσ, representing interesting lead compounds for further investigation.
- 10 August 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 6 (9) , 982-986
Identification of Bidentate Salicylic Acid Inhibitors of PTP1B
PTP1B is a master regulator in the insulin and leptin metabolic pathways. Hyper-activated PTP1B results in insulin resistance and is viewed as a key factor in the onset of type II diabetes and obesity. Moreover, inhibition of PTP1B expression in cancer cells dramatically inhibits cell growth in vitro and in vivo. Herein, we report the computationally guided optimization of a salicylic acid-based PTP1B inhibitor 6, identifying new and more potent bidentate PTP1B inhibitors, such as 20h, which exhibited a > 4-fold improvement in activity. In CHO-IR cells, 20f, 20h, and 20j suppressed PTP1B activity and restored insulin receptor phosphorylation levels. Notably, 20f, which displayed a 5-fold selectivity for PTP1B over the closely related PTPσ protein, showed no inhibition of PTP-LAR, PRL2 A/S, MKPX, or papain. Finally, 20i and 20j displayed nanomolar inhibition of PTPσ, representing interesting lead compounds for further investigation.
- Open Access
- 25 July 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (29) , 27461-27477
STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation
STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation
- 25 July 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (29) , 27461-27477
Open AccessSTAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation
STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation